This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Development

Biotech Showcase™ 2016: Interview: Diagnostics company VisionGate migrates into therapeutics

Posted by on 11 July 2017
Share this article

VisionGate founder, chairman and CEO Dr. Alan Nelson explains to Mike Ward, Informa Pharma Insights global director of content, what has motivated the company to migrate from being a diagnostics business to one having a therapeutics focus. Having developed a non-invasive test for lung cancer, LuCED, which also has indicated an ability to detect various tumor types and stages of lung cancer, including Stage I and even dysplasia, VisionGate acquired exclusive rights to the University of Colorado’s patent for the use of the drug Iloprost, a drug currently used to treat various lung diseases such as pulmonary arterial hypertension, in the prevention of lung cancer. Dr. Nelson details how the company and the University of Colorado will conduct a Phase IIB validation trial where LuCED is compared with biopsy, leading to the Phase III trial in dysplasia.

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down